Conference held August 20-23, 2007 in Seattle, Washington. GeoVax
HIV/AIDS human trial results were presented by Dr. Paul Goepfert, MD in
a talk "HIV-1 DNA Prime followed by Recombinant MVA Boost is Well
Tolerated and Immunogenic When Administered to Healthy Seronegative
Adults." Dr. Goepfert, from the University of Alabama-Birmingham, is
Protocol Chair of HVTN 065, a series of human clinical trials currently
evaluating GeoVax's HIV/AIDS vaccine. GeoVax HIV/AIDS vaccine trial
data was presented to over 900 AIDS researchers at the week long
conference. Conference Chair, Dr. Lawrence Corey stated, "It has become
clear that a preventative vaccine is essential to controlling the
global AIDS epidemic." The AIDS Vaccine 2007 Conference was organized
under the guidance of the Global HIV Vaccine Enterprise, an alliance of
independent global organizations dedicated to accelerating preventative
AIDS vaccine development. The conference reported the AIDS epidemic
continuing as a global threat with the disease increasing in every
region of the world, especially East and Central Asia and Eastern
Europe where AIDS incidence was 21% higher in 2006 than in 2004.
Key GeoVax HIV/AIDS Vaccine Human Trial conclusions presented at the
AIDS Vaccine 2007 Conference included:
-- GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate
anti-HIV/AIDS immune responses) at both low (1/10th) dose and full
-- GeoVax vaccines were well tolerated with no or mild local and
reactions in the majority of trial participants.
-- 80% of both the low and full dose trial participants responded to the
vaccine which stimulated highly desirable anti-HIV T-cell (white
blood cell) and antibody responses.
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved